ZTS Net Income Growth
0.15%TTM
Period ending:
ZTS TTM Net Income YoY %%
164.27%-63.94%
2012-12-312026-06-30
Source: Financial Modeling Prep (FMP). Trailing twelve months (TTM). TTM flows use four complete reported quarters. Growth compares with the corresponding period one year earlier.
ZTS net income growth history
Year-over-year net income growth rate. The available trailing twelve months (ttm) series contains 55 observations from Dec 31, 2012 to Jun 30, 2026.
| Period ending | Net Income Growth |
|---|---|
| 0.1531% | |
| 4.9643% | |
| 7.5221% | |
| 9.0947% | |
| 11.4334% | |
| 5.3116% | |
| 6.058% | |
| 6.5789% | |
| 5.9196% | |
| 15.4515% | |
| 10.8798% | |
| 10.3048% | |
| 5.8852% | |
| -0.0965% | |
| 3.7801% | |
| 4.2886% | |
| 9.4814% | |
| 16.8546% | |
| 24.359% | |
| 19.1822% | |
| 18.0581% | |
| 10.1179% | |
| 9.2% | |
| 13.8261% | |
| 17.6% | |
| 16.0663% | |
| 5.042% | |
| 25.5155% | |
| 23.3184% | |
| 41.9223% | |
| 65.2778% | |
| 24.2263% | |
| 26.9932% | |
| 14.386% | |
| 5.2375% | |
| 35.9942% | |
| 37.4022% | |
| 126.1905% | |
| 142.1829% | |
| 55.5305% | |
| 52.1429% | |
| -36.2563% | |
| -41.8525% | |
| -21.1744% | |
| -20.3036% | |
| 14.2582% | |
| 15.6746% | |
| 44.473% | |
| 25.4762% | |
| 11.6129% | |
| 15.5963% | |
| -14.5055% | |
| 8.5271% | |
| 66.0714% | |
| 77.9592% |
Compare net income growth
Other companies in Healthcare. Each page shows its own reporting periods and currency.
- Lilly (Eli) (LLY) net income growth
- Johnson & Johnson (JNJ) net income growth
- AbbVie (ABBV) net income growth
- UnitedHealth Group (UNH) net income growth
- Merck & Co. (MRK) net income growth
- Thermo Fisher Scientific (TMO) net income growth
- Amgen (AMGN) net income growth
- Gilead Sciences (GILD) net income growth
Compare all covered stocks by net income growth →
All ZTS financial metrics · ZTS stock overview · How to interpret financial metrics
